Toll-Like Receptor-Based Strategies for Cancer Immunotherapy

TLR5 agonist entolimod reduces the adverse toxicity of TNF while preserving its antitumor effects

(2020) Gary J. Haderski et al.   PLoS One

IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer

(2020) Margaux Hubert et al.   Science Immunology

Harnessing the Complete Repertoire of Conventional Dendritic Cell Functions for Cancer Immunotherapy

(2020) Lukas Amon et al.   Pharmaceutics

Inducible MyD88/CD40 synergizes with IL-15 to enhance antitumor efficacy of CAR-NK cells

(2020) Xiaomei Wang et al.   Blood Advances

Modulation of the Innate Immune Response by Targeting Toll-like Receptors: A Perspective on Their Agonists and Antagonists

(2020) Stefano Federico et al.   JOURNAL OF MEDICINAL CHEMISTRY

Macrophage-based approaches for cancer immunotherapy

(2020) Nicholas R. Anderson et al.   CANCER RESEARCH

Toll‐like receptor‐2/7‐mediated T cell activation: An innate potential to augment CD8 + T cell cytokine production

(2020) Julian J. Freen‐van Heeren   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

The Influence of Chimeric Antigen Receptor Structural Domains on Clinical Outcomes and Associated Toxicities

(2020) Ashleigh S. Davey et al.   Cancers

A novel TLR4 binding protein, 40S ribosomal protein S3, has potential utility as an adjuvant in a dendritic cell-based vaccine

(2019) Hyun Jin Park et al.   Journal for ImmunoTherapy of Cancer

Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies

(2019) Matthew R. Collinson-Pautz et al.   LEUKEMIA

Oligodeoxynucleotides ODN 2006 and M362 Exert Potent Adjuvant Effect through TLR-9/-6 Synergy to Exaggerate Mammaglobin-A Peptide Specific Cytotoxic CD8+T Lymphocyte Responses against Breast Cancer Cells

(2019) Duaa Babaer et al.   Cancers

Combined Adjuvant of Poly I:C Improves Antitumor Effects of CAR-T Cells

(2019) Shengmeng Di et al.   Frontiers in Oncology

A Toll-like receptor 3 (TLR3) agonist ARNAX for therapeutic immunotherapy

(2019) Tsukasa Seya et al.   ADVANCED DRUG DELIVERY REVIEWS

TLR9 agonist adsorbed to alum adjuvant prevents asthma‐like responses induced by Blomia tropicalis mite extract

(2019) Fernanda P. B. Nunes et al.   JOURNAL OF LEUKOCYTE BIOLOGY

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients

(2019) Marit M. Melssen et al.   Journal for ImmunoTherapy of Cancer

The TLR9 agonist (GNKG168) induces a unique immune activation pattern in vivo in children with minimal residual disease positive acute leukemia: Results of the TACL T2009-008 phase I study

(2019) Rebecca Ronsley et al.   PEDIATRIC HEMATOLOGY AND ONCOLOGY

Toll-Like Receptor 7 Activation Enhances CD8+ T Cell Effector Functions by Promoting Cellular Glycolysis

(2019) Qian Li et al.   Frontiers in Immunology

Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential

(2019) Mohammad-Hossein Haddadi et al.   BLOOD REVIEWS

Combined Vaccination with NY-ESO-1 Protein, Poly-ICLC, and Montanide Improves Humoral and Cellular Immune Responses in Patients with High-Risk Melanoma

(2019) Anna Pavlick et al.   Cancer Immunology Research

TLR9 activation cooperates with T cell checkpoint blockade to regress poorly immunogenic melanoma

(2019) Matthew J. Reilley et al.   Journal for ImmunoTherapy of Cancer

TLR 7/8 agonist reverses oxaliplatin resistance in colorectal cancer via directing the myeloid-derived suppressor cells to tumoricidal M1-macrophages

(2019) Zhipeng Liu et al.   CANCER LETTERS

Directing toll-like receptor signaling in macrophages to enhance tumor immunotherapy

(2019) Qin Zeng et al.   CURRENT OPINION IN BIOTECHNOLOGY

Vaccine immunotherapy with ARNAX induces tumor-specific memory T cells and durable anti-tumor immunity in mouse models

(2018) Yohei Takeda et al.   CANCER SCIENCE

TLR-mediated metabolic reprogramming in the tumor microenvironment: potential novel strategies for cancer immunotherapy

(2018) Lan Huang et al.   Cellular & Molecular Immunology

CpG ODN1826 as a Promising Mucin1-Maltose-Binding Protein Vaccine Adjuvant Induced DC Maturation and Enhanced Antitumor Immunity

(2018) Jing Jie et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

TLR-3 Stimulation Skews M2 Macrophages to M1 Through IFN-αβ Signaling and Restricts Tumor Progression

(2018) Aurobind Vidyarthi et al.   Frontiers in Immunology

The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial

(2018) Rhea N. Coler et al.   npj Vaccines

Recent clinical trends in Toll-like receptor targeting therapeutics

(2018) Muhammad Ayaz Anwar et al.   MEDICINAL RESEARCH REVIEWS

Both Type I and Type II Interferons Can Activate Antitumor M1 Macrophages When Combined With TLR Stimulation

(2018) Elisabeth Müller et al.   Frontiers in Immunology

Trial Watch: Toll-like receptor agonists in cancer immunotherapy

(2018) Melody Smith et al.   OncoImmunology

Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer

(2017) Shikhar Mehrotra et al.   Journal of Hematology & Oncology

Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells

(2017) Y Lai et al.   LEUKEMIA

Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40

(2017) Aaron E. Foster et al.   MOLECULAR THERAPY

Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy

(2017) V Mett et al.   ONCOGENE

NK cell-based immunotherapy for cancer

(2017) Fang Fang et al.   SEMINARS IN IMMUNOLOGY

Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy

(2017) Misako Matsumoto et al.   Frontiers in Immunology

Topical Imiquimod Plus Nab-paclitaxel for Breast Cancer Cutaneous Metastases

(2017) Lupe G. Salazar et al.   JAMA Oncology

A Randomized Trial of TLR-2 agonist CADI-05 targeting desmocollin-3 for advanced non-small-cell lung cancer

(2016) C.P. Belani et al.   ANNALS OF ONCOLOGY

Abstract 4885: Intratumoral injection of G100 (TLR4 agonist glycopyranosyl lipid A) modulates tumor microenvironment and induces CD8 T cell-dependent, systemic anti-tumor immunity

(2016) Hailing Lu et al.   CANCER RESEARCH

Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN

(2016) Laura Q.M. Chow et al.   CLINICAL CANCER RESEARCH

Recent progress in the development of Toll-like receptor (TLR) antagonists

(2016) Mahesh Chandra Patra et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Immunological evaluation of colonic delivered Hepatitis B surface antigen loaded TLR-4 agonist modified solid fat nanoparticles

(2016) Kantrol Kumar Sahu et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Intratumoral injection of a CpG oligonucleotide reverts resistance to PD-1 blockade by expanding multifunctional CD8+T cells

(2016) Shu Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Trial Watch: Immunotherapy plus radiation therapy for oncological indications

(2016) Erika Vacchelli et al.   OncoImmunology

A randomized pilot trial testing the safety and immunologic effects of a MAGE-A3 protein plus AS15 immunostimulant administered into muscle or into dermal/subcutaneous sites

(2015) Craig L. Slingluff et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker

(2015) Christina Müller et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

MGN1703, an immunomodulator and toll-like receptor 9 (TLR-9) agonist: From bench to bedside

(2015) Burghardt Wittig et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

The efficacy of adjuvant immunochemotherapy with OK-432 after curative resection of gastric cancer: an individual patient data meta-analysis of randomized controlled trials

(2015) Mari S. Oba et al.   Gastric Cancer

Imiquimod in cervical, vaginal and vulvar intraepithelial neoplasia: A review

(2015) C.J. de Witte et al.   GYNECOLOGIC ONCOLOGY

Poly(I:C) as cancer vaccine adjuvant: Knocking on the door of medical breakthroughs

(2015) Rachid Ammi et al.   PHARMACOLOGY & THERAPEUTICS

Adoptive Cell Therapy—Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors

(2015) Steven A. Feldman et al.   SEMINARS IN ONCOLOGY

TRAIL-mediated killing of acute lymphoblastic leukemia by plasmacytoid dendritic cell-activated natural killer cells

(2015) Martin Lelaidier et al.   Oncotarget

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

(2014) David A. Smith et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

TLR8 signaling enhances tumor immunity by preventing tumor-induced T-cell senescence

(2014) J. Ye et al.   EMBO Molecular Medicine

TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells

(2014) Francesca Bellora et al.   EUROPEAN JOURNAL OF IMMUNOLOGY

Toll-like receptor agonists: a patent review (2011 – 2013)

(2014) Waleed M Hussein et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Toll-like receptors and B cells: functions and mechanisms

(2014) Claire M. Buchta et al.   IMMUNOLOGIC RESEARCH

Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

(2014) Hans-Joachim Schmoll et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Clinical use of dendritic cells for cancer therapy

(2014) Sébastien Anguille et al.   LANCET ONCOLOGY

Clinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer

(2014) Julia Scheiermann et al.   VACCINE

Dendritic cell subsets require cis-activation for cytotoxic CD8 T-cell induction

(2014) A Nicole Desch et al.   Nature Communications

Direct Type I IFN but Not MDA5/TLR3 Activation of Dendritic Cells Is Required for Maturation and Metabolic Shift to Glycolysis after Poly IC Stimulation

(2014) Austin Pantel et al.   PLOS BIOLOGY

TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells

(2013) Hongliang Fang et al.   Cellular & Molecular Immunology

Intratumoral Anti-CTLA-4 Therapy: Enhancing Efficacy While Avoiding Toxicity

(2013) A. Marabelle et al.   CLINICAL CANCER RESEARCH

Randomized, Double-Blind, Placebo-Controlled, Dose-Escalating Phase I, Healthy Subjects Study of Intravenous OPN-305, a Humanized Anti-TLR2 Antibody

(2013) M Reilly et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck

(2013) Jean-Pascal Machiels et al.   INVESTIGATIONAL NEW DRUGS

Macrophages Are More Potent Immune Suppressors Ex Vivo Than Immature Myeloid-Derived Suppressor Cells Induced by Metastatic Murine Mammary Carcinomas

(2013) M. J. Hamilton et al.   JOURNAL OF IMMUNOLOGY

In vitro induction of potent tumor-specific cytotoxic T lymphocytes using TLR agonist-activated AML-DC

(2013) Maryam Nourizadeh et al.   Targeted Oncology

Toll-Like Receptor Signaling

(2013) K.-H. Lim et al.   Cold Spring Harbor Perspectives in Biology

Phosphatidylserine-Targeting Antibody Induces M1 Macrophage Polarization and Promotes Myeloid-Derived Suppressor Cell Differentiation

(2013) Y. Yin et al.   Cancer Immunology Research

Roles of toll-like receptors in Cancer: A double-edged sword for defense and offense

(2012) Shaherin Basith et al.   ARCHIVES OF PHARMACAL RESEARCH

Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers

(2012) Zhen Huang et al.   BIOMATERIALS

Critical role of Toll-like receptor signaling in NK cell activation

(2012) Qie Guo et al.   CHINESE SCIENCE BULLETIN

Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells

(2012) Barbara Drobits et al.   JOURNAL OF CLINICAL INVESTIGATION

Macrophage plasticity and polarization: in vivo veritas

(2012) Antonio Sica et al.   JOURNAL OF CLINICAL INVESTIGATION

Molecular and Cellular Response Profiles Induced by the TLR4 Agonist-Based Adjuvant Glucopyranosyl Lipid A

(2012) Stacie L. Lambert et al.   PLoS One

CpG ODN107 potentiates radiosensitivity of human glioma cells via TLR9-mediated NF-κB activation and NO production

(2012) Xiaoli Li et al.   TUMOR BIOLOGY

A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer

(2011) C. Manegold et al.   ANNALS OF ONCOLOGY

Activation of Toll-like Receptor 5 on Breast Cancer Cells by Flagellin Suppresses Cell Proliferation and Tumor Growth

(2011) Z. Cai et al.   CANCER RESEARCH

TLR2 Agonist PSK Activates Human NK Cells and Enhances the Antitumor Effect of HER2-Targeted Monoclonal Antibody Therapy

(2011) H. Lu et al.   CLINICAL CANCER RESEARCH

VTX-1463, a novel TLR8 agonist for the treatment of allergic rhinitis

(2011) Friedrich Horak   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The Toll-Like Receptor 4 Agonist Monophosphoryl Lipid A Augments Innate Host Resistance to Systemic Bacterial Infection

(2011) Christopher D. Romero et al.   INFECTION AND IMMUNITY

Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2011) Vera Hirsh et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients with previously treated chronic lymphocytic leukemia

(2011) Clive S. Zent et al.   LEUKEMIA & LYMPHOMA

When Toll-like receptor and T-cell receptor signals collide: a mechanism for enhanced CD8 T-cell effector function

(2010) D. Geng et al.   BLOOD

Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy

(2010) Gerty Schreibelt et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

TLR3 induction by anticancer drugs potentiates poly I:C-induced tumor cell apoptosis

(2010) Manabu Taura et al.   CANCER SCIENCE

The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice

(2010) Fang Ma et al.   Cellular & Molecular Immunology

Enhancement of antitumor effect using dendritic cells activated with natural killer cells in the presence of Toll-like receptor agonist

(2010) Thanh Nhan Nguyen Pham et al.   EXPERIMENTAL AND MOLECULAR MEDICINE

TLR1/2, TLR7, and TLR9 Signals Directly Activate Human Peripheral Blood Naive and Memory B Cell Subsets to Produce Cytokines, Chemokines, and Hematopoietic Growth Factors

(2010) Sudhanshu Agrawal et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Differential but Direct Abolishment of Human Regulatory T Cell Suppressive Capacity by Various TLR2 Ligands

(2010) H. H. Oberg et al.   JOURNAL OF IMMUNOLOGY

TLR-based immune adjuvants

(2010) Folkert Steinhagen et al.   VACCINE

Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection

(2009) Richard T Lester et al.   AIDS

Toll-like Receptors 3 and 7 Agonists Enhance Tumor Cell Lysis by Human    T Cells

(2009) H. Shojaei et al.   CANCER RESEARCH

The contribution of direct TLR signaling to T cell responses

(2009) Adeeb H. Rahman et al.   IMMUNOLOGIC RESEARCH

AS04, an Aluminum Salt- and TLR4 Agonist-Based Adjuvant System, Induces a Transient Localized Innate Immune Response Leading to Enhanced Adaptive Immunity

(2009) A. M. Didierlaurent et al.   JOURNAL OF IMMUNOLOGY

Toll-like Receptor 4 Signaling Promotes Tumor Growth

(2009) Che-Hsin Lee et al.   JOURNAL OF IMMUNOTHERAPY

T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy

(2008) R. Houot et al.   BLOOD

Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors

(2008) Masashi Murata   CANCER SCIENCE

Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC- -dependent mechanism

(2008) A. Paone et al.   CARCINOGENESIS

Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity

(2008) Nicole Asprodites et al.   FASEB JOURNAL

Toll-like receptor 9 (TLR9) agonists in the treatment of cancer

(2008) A M Krieg   ONCOGENE

The TLR3 agonist poly(I:C) targets CD8+ T cells and augments their antigen-specific responses upon their adoptive transfer into naïve recipient mice

(2008) Mohamed L. Salem et al.   VACCINE

A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro

(2008) H. Navabi et al.   VACCINE